{"id":23873,"date":"2023-05-23T09:45:34","date_gmt":"2023-05-23T14:45:34","guid":{"rendered":"https:\/\/cdtrp.ca\/?p=23873"},"modified":"2023-05-23T09:45:34","modified_gmt":"2023-05-23T14:45:34","slug":"act-call-for-proposals-biotech","status":"publish","type":"post","link":"https:\/\/cdtrp.ca\/en\/act-call-for-proposals-biotech\/","title":{"rendered":"ACT Call for Proposals: Evaluate Canadian Biotechnologies with Randomized Controlled Trials"},"content":{"rendered":"
<\/a><\/span><\/div>
<\/div>

Call for Proposals: Evaluate Canadian Biotechnologies with Randomized Controlled Trials<\/strong><\/h4>\n

The Accelerating Clinical Trials\/Acc\u00e9l\u00e9rer les Essais Cliniques (ACT\/AEC<\/a>)<\/strong> Consortium is pleased to announce a call for proposals entitled: Canadian Biotechnologies with Randomized Controlled Trials<\/strong><\/em>.<\/strong><\/p>\n<\/div>

<\/div><\/div><\/div><\/div>
OBJECTIVES<\/strong><\/h5>\n

Most biotechnologies require randomized controlled trials demonstrating efficacy and safety to obtain regulatory approvals. The objective of this request for applications is to fund trials evaluating products from Canadian-controlled biotechnology companies in partnership with ACT Network clinical trialists.<\/p>\n

Through this RFA, ACT aims to provide foundational support to Canada\u2019s Biomanufacturing and Life Sciences Strategy (BLSS) by enabling Canada\u2019s best researchers and companies to undertake the clinical trials efficiently, aligned with BLSS, Pillar 3: Growing Businesses by Doubling Down on Existing and Emerging Areas of Strength; the goal being to improve the health of Canadians.<\/p>\n<\/div><\/div><\/div>

APPLY NOW!<\/strong><\/h5>\n

For a trial to be eligible, it must fulfill each of the following points:<\/p>\n